Durgaprasad Laveti, Manoj Kumar, R Hemalatha, Ramakrishna Sistla, V G M Naidu, Venu Talla, Vinod Verma, Navrinder Kaur, Ravinder Nagpal
{"title":"慢性疾病的抗炎治疗综述","authors":"Durgaprasad Laveti, Manoj Kumar, R Hemalatha, Ramakrishna Sistla, V G M Naidu, Venu Talla, Vinod Verma, Navrinder Kaur, Ravinder Nagpal","doi":"10.2174/18715281113129990053","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammation is viewed as one of the major causes for the development of different diseases like cancer, cardiovascular disease, diabetes, obesity, osteoporosis, rheumatoid arthritis, inflammatory bowel disease, asthma, and CNS related diseases such as depression and parkinson's disease; and this fervent phenomenon provides space for understanding different inflammatory markers. Increasing evidences have elucidated the outcome of inflammatory pathways dysregulation resulting in many symptoms of chronic diseases. The detection of transcription factors such as nuclear factor kappa-B (NF-κB), STAT and their gene products such as COX-2, cytokines, chemokines and chemokine receptors has laid molecular foundation for the important role of inflammation in chronic diseases in which the NF-κB is reported as a major mediator which makes a possible way for the development of new therapeutic approaches using synthetic and natural compounds that might eventually decrease the prevalence of these diseases. Even if many inflammatory markers like TNF-α, IL-1, IL-6, IL-8 and C-reactive protein (CRP) are reported to be the major key factors with proved role in several inflammatory diseases, IL-1 and TNF-α are the important cytokines that can induce the expression of NF-κB which is the potential target in these inflammatory diseases. This review aims to explore and summarize that how some drugs and natural compounds show their modulatory activity in inflammatory pathways and chronic inflammatory markers in these inflammatory diseases. </p>","PeriodicalId":13680,"journal":{"name":"Inflammation & allergy drug targets","volume":"12 5","pages":"349-61"},"PeriodicalIF":0.0000,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"244","resultStr":"{\"title\":\"Anti-inflammatory treatments for chronic diseases: a review.\",\"authors\":\"Durgaprasad Laveti, Manoj Kumar, R Hemalatha, Ramakrishna Sistla, V G M Naidu, Venu Talla, Vinod Verma, Navrinder Kaur, Ravinder Nagpal\",\"doi\":\"10.2174/18715281113129990053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inflammation is viewed as one of the major causes for the development of different diseases like cancer, cardiovascular disease, diabetes, obesity, osteoporosis, rheumatoid arthritis, inflammatory bowel disease, asthma, and CNS related diseases such as depression and parkinson's disease; and this fervent phenomenon provides space for understanding different inflammatory markers. Increasing evidences have elucidated the outcome of inflammatory pathways dysregulation resulting in many symptoms of chronic diseases. The detection of transcription factors such as nuclear factor kappa-B (NF-κB), STAT and their gene products such as COX-2, cytokines, chemokines and chemokine receptors has laid molecular foundation for the important role of inflammation in chronic diseases in which the NF-κB is reported as a major mediator which makes a possible way for the development of new therapeutic approaches using synthetic and natural compounds that might eventually decrease the prevalence of these diseases. Even if many inflammatory markers like TNF-α, IL-1, IL-6, IL-8 and C-reactive protein (CRP) are reported to be the major key factors with proved role in several inflammatory diseases, IL-1 and TNF-α are the important cytokines that can induce the expression of NF-κB which is the potential target in these inflammatory diseases. This review aims to explore and summarize that how some drugs and natural compounds show their modulatory activity in inflammatory pathways and chronic inflammatory markers in these inflammatory diseases. </p>\",\"PeriodicalId\":13680,\"journal\":{\"name\":\"Inflammation & allergy drug targets\",\"volume\":\"12 5\",\"pages\":\"349-61\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"244\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammation & allergy drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/18715281113129990053\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation & allergy drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/18715281113129990053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 244
摘要
炎症被认为是不同疾病发展的主要原因之一,如癌症、心血管疾病、糖尿病、肥胖、骨质疏松症、类风湿性关节炎、炎症性肠病、哮喘和中枢神经系统相关疾病,如抑郁症和帕金森病;这种狂热的现象为理解不同的炎症标志物提供了空间。越来越多的证据表明炎症通路失调导致许多慢性疾病的症状。转录因子如核因子κ b (NF-κB), STAT及其基因产物如COX-2,细胞因子,趋化因子和趋化因子受体的检测为炎症在慢性疾病中的重要作用奠定了分子基础,其中NF-κB被报道为主要介质,这为开发新的治疗方法提供了可能的途径,使用合成和天然化合物最终可能降低这些疾病的患病率。尽管许多炎症标志物如TNF-α、IL-1、IL-6、IL-8和c反应蛋白(C-reactive protein, CRP)已被报道为几种炎症疾病的主要关键因子,但IL-1和TNF-α是诱导NF-κB表达的重要细胞因子,而NF-κB是这些炎症疾病的潜在靶点。本文旨在探讨和总结一些药物和天然化合物如何在这些炎症性疾病中显示其对炎症途径和慢性炎症标志物的调节活性。
Anti-inflammatory treatments for chronic diseases: a review.
Inflammation is viewed as one of the major causes for the development of different diseases like cancer, cardiovascular disease, diabetes, obesity, osteoporosis, rheumatoid arthritis, inflammatory bowel disease, asthma, and CNS related diseases such as depression and parkinson's disease; and this fervent phenomenon provides space for understanding different inflammatory markers. Increasing evidences have elucidated the outcome of inflammatory pathways dysregulation resulting in many symptoms of chronic diseases. The detection of transcription factors such as nuclear factor kappa-B (NF-κB), STAT and their gene products such as COX-2, cytokines, chemokines and chemokine receptors has laid molecular foundation for the important role of inflammation in chronic diseases in which the NF-κB is reported as a major mediator which makes a possible way for the development of new therapeutic approaches using synthetic and natural compounds that might eventually decrease the prevalence of these diseases. Even if many inflammatory markers like TNF-α, IL-1, IL-6, IL-8 and C-reactive protein (CRP) are reported to be the major key factors with proved role in several inflammatory diseases, IL-1 and TNF-α are the important cytokines that can induce the expression of NF-κB which is the potential target in these inflammatory diseases. This review aims to explore and summarize that how some drugs and natural compounds show their modulatory activity in inflammatory pathways and chronic inflammatory markers in these inflammatory diseases.